Drug Trial Radar · NCT00068770
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Last checked: Nov 19, 2026Latest source record: Mar 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
35
Actual
Start
Oct 2003
Primary completion
May 2005
Study completion May 2006
Sponsor
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 11, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
Conditions
- Brain and Central Nervous System Tumors
Interventions
radiation therapyRadiation
Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
CelecoxibDrug
Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of Hepatic Enzyme Inducing Drugs Such as Anticonvulsants, on the PK of CelecoxibTime frame: First dose of celecoxib through completion of radiation, 6 weeks.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.